woman working in lab

Moving Prenatal Screening and Liquid Biopsy Forward

Shifting the Paradigm of Prenatal Screening

The name of our non-invasive prenatal test (NIPT) is appropriately called “UNITY” as it brings together fetal screening for aneuploidies and recessive conditions. It also represents uniting pregnant patients in more equitable care.

iStock-1135307739-scaled-e1656374638168
Unity logo

UNITY Screen™ is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw at 10+ weeks into pregnancy. We are able to quantify the tiny DNA changes floating in cell-free DNA using our molecular counting technology.

UNITY does not require a paternal blood sample to assess fetal risk, supporting more equitable care and enabling more pregnancies at risk to be affected with recessive conditions to be identified early in pregnancy as compared to traditional carrier screening.

Learn More

Uncovering What’s Possible for Liquid Biopsy

Northstar Select™ and Northstar Response™ are liquid biopsy tests currently available for research use only.

Therapy Selection

The Northstar Select™ provides a prioritized list of mutations that are present in the tumor. The types of mutations detected include deletions, insertions, and point-mutations. At the same time, it helps rule-in / rule-out relationship of mutations to drugs and provides an accurate read on the covered genes.

Details

  • Broad genomic coverage
  • Low limit of detection enabled by our molecular counting technology
closeup of a hand holding a test tube with separated blood and plasma

Therapy Response

The Northstar Response™ provides longitudinal determination of cancer burden via methylation assessment.

Details

  • Multi cancer methylation signature (nucleotides are methylated in specific locations in cancers)
  • Quantification of changes in tumor burden enabled by our molecular counting technology
asian female scientist putting blood in Hamilton machine

Interested in a research collaboration? Get in touch or Discover Our Technology

Get In Touch

News & Media

View All

Press Releases

BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen

Read Article

Media Coverage

BillionToOne Ranked a Top Healthcare Technology Company of 2022

Read Article

Press Releases

BillionToOne launches oncology liquid biopsy products for research use & announces clinical research collaboration with UCSD

Read Article

Media Coverage

BillionToOne Closes $125M Series C Funding with Premier Global Investors

Read Article

Media Coverage

BillionToOne CEO Oguzhan Atay, PhD, named in Top 25 CEOs in Biotech of 2022 by the Healthcare Technology Report

Read Article

Media Coverage

BillionToOne’s Senior Vice President of Sales and Commercial Operations Named One of the Top 25 Women Leaders in Biotechnology of 2021

Read Article

Media Coverage

BillionToOne’s Nancy Johnson Named One of the Top 25 Women Leaders in Biotechnology of 2021

Read Article

Media Coverage

BillionToOne Appoints Nipun Soni, CFA, CPA as the First Chief Financial Officer

Read Article

Media Coverage

BillionToOne Raises $55M in Series B Financing

Read Article

Media Coverage

BillionToOne Closes $55M Series B Funding, Builds Out a 36,000 Sqft Space to Meet Growing Demand

Read Article